Improvement of Diurnal Blood Pressure Variation by Azilsartan
نویسندگان
چکیده
منابع مشابه
Improvement of Diurnal Blood Pressure Variation by Azilsartan
Background Azilsartan is an angiotensin II receptor blocker with a potent antihypertensive effect. Methods In a multicenter, prospective, open-label study, 265 patients with poor blood pressure control despite treatment with other angiotensin II receptor blockers were switched to 20 mg/day of azilsartan (patients on standard dosages) or 40 mg/day of azilsartan (patients on high dosages). Re...
متن کاملImpaired diurnal blood pressure variation and all-cause mortality.
BACKGROUND Most healthy people exhibit a decrease in systolic blood pressure (SBP) at night. A drop of <10% from mean daytime values, "non-dipping," is associated with kidney disease and cardiovascular events. We hypothesized that non-dipping would predict all-cause mortality. METHODS Consecutive patients referred for ambulatory blood pressure (BP) monitoring at the Cleveland Clinic between 1...
متن کاملDiurnal blood pressure variation in progressive autonomic failure.
To investigate the role of the autonomic nervous system (ANS) in the generation of the circadian blood pressure (BP) variation, the degree of impairment of the ANS was related to the results of ambulatory BP recordings in 212 patients with progressive autonomic failure due to familial amyloid polyneuropathy. On the basis of BP and/or heart rate (HR) responses to the Valsalva maneuver, 60 degree...
متن کاملEvaluation of the diurnal intraocular pressure fluctuations and blood pressure under dehydration due to fasting
Introduction: This study aimed to investigate the diurnal intraocular pressure fluctuations under dehydration conditions and the relationship between the intraocular pressure fluctuations and blood pressure. Methods: The intraocular pressures (IOP), body weights, as well as systolic and diastolic blood pressures (SBP, DBP) of 36 fasting healthy volunteers were recorded at 8:00 a.m. and 5:00 p.m...
متن کاملAzilsartan/chlorthalidone combination therapy for blood pressure control
BACKGROUND Edarbyclor(®) is a combined angiotensin receptor blocker (ARB) and thiazide-like diuretic (azilsartan and chlorthalidone), and was approved on December 20, 2011 by the US Food and Drug Administration (FDA) for hypertension management. OBJECTIVE To review the pharmacology, pharmacokinetics, efficacy, safety, tolerability, and role of azilsartan plus chlorthalidone for hypertension m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Medicine Research
سال: 2018
ISSN: 1918-3003,1918-3011
DOI: 10.14740/jocmr3228w